Evidence map›Paper›PMID 31203377›Full record

ArticleDiabetologia2019

Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium.

Robert W Koivula, Ian M Forgie, Azra Kurbasic, Ana Viñuela, Alison Heggie, Giuseppe N Giordano, Tue H Hansen, Michelle Hudson, Anitra D M Koopman, Femke Rutters and 41 more

Full text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetologia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Curating a longitudinal research resource using linked primary care EHR data-a UK Biobank case study.Journal of the American Medical Informatics Association : JAMIA · 2022
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

51 authors.

Robert W KoivulaDepartment of Clinical Sciences, Lund University Diabetes Centre, Genetic and Molecular Epidemiology Unit, CRC, Skåne University Hospital Malmö, Building 91, Level 10, Jan Waldenströms gata 35, SE-205 02, Malmö, Sweden.ORCID 0000-0002-1646-4163
Ian M ForgiePopulation Health & Genomics, Medical Research Institute, University of Dundee, Dundee, DD1 9SY, UK.
Azra KurbasicDepartment of Clinical Sciences, Lund University Diabetes Centre, Genetic and Molecular Epidemiology Unit, CRC, Skåne University Hospital Malmö, Building 91, Level 10, Jan Waldenströms gata 35, SE-205 02, Malmö, Sweden.
Ana ViñuelaDepartment of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland.
Alison HeggieInstitute of Cellular Medicine (Diabetes), Newcastle University, Newcastle upon Tyne, UK.
Giuseppe N GiordanoDepartment of Clinical Sciences, Lund University Diabetes Centre, Genetic and Molecular Epidemiology Unit, CRC, Skåne University Hospital Malmö, Building 91, Level 10, Jan Waldenströms gata 35, SE-205 02, Malmö, Sweden.
Tue H HansenThe Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.
Michelle HudsonNIHR Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, UK.
Anitra D M KoopmanDepartment of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, the Netherlands.
Femke RuttersDepartment of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, the Netherlands.
Maritta SiloahoDepartment of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.
Kristine H AllinThe Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.
Søren BrageMRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, UK.
Caroline A BrorssonDepartment of Bio and Health Informatics, Technical University of Denmark, Lyngby, Denmark.
Adem Y DawedPopulation Health & Genomics, Medical Research Institute, University of Dundee, Dundee, DD1 9SY, UK.
Federico De MasiDepartment of Bio and Health Informatics, Technical University of Denmark, Lyngby, Denmark.
Christopher J GrovesOxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Tarja KokkolaDepartment of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.
Anubha MahajanWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Mandy H PerryNIHR Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, UK.
Simone P RauhDepartment of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, the Netherlands.
Martin RidderstråleDepartment of Clinical Sciences, Clinical Obesity, Skåne University Hospital Malmö, Lund University, Malmö, Sweden.
Harriet J A TeareHeLEX, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Headington, Oxford, UK.
E Louise ThomasResearch Centre for Optimal Health, Department of Life Sciences, University of Westminster, London, UK.
Andrea TuraInstitute of Neurosciences, National Research Council, Padova, Italy.
Henrik VestergaardThe Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.
Tom WhiteMRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, UK.
Jerzy AdamskiInstitute of Epidemiology II, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health (GmbH), Neuherberg, Germany.
Jimmy D BellResearch Centre for Optimal Health, Department of Life Sciences, University of Westminster, London, UK.
Joline W BeulensDepartment of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, the Netherlands.
Søren BrunakDepartment of Bio and Health Informatics, Technical University of Denmark, Lyngby, Denmark.
Emmanouil T DermitzakisDepartment of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland.
Philippe FroguelDepartment of Genomics of Common Disease, School of Public Health, Imperial College London, London, UK.
Gary FrostNutrition and Dietetics Research Group, Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Imperial College London, Hammersmith Campus, London, UK.
Ramneek GuptaDepartment of Bio and Health Informatics, Technical University of Denmark, Lyngby, Denmark.
Torben HansenThe Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.
Andrew HattersleyNIHR Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, UK.
Bernd JablonkaSanofi-Aventis Deutschland GmbH, R&D, Frankfurt am Main, Germany.
Jane KayeHeLEX, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Headington, Oxford, UK.
Markku LaaksoDepartment of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.
Timothy J McDonaldNIHR Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, UK.
Oluf PedersenThe Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.
Jochen M SchwenkScience for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH - Royal Institute of Technology, Stockholm, Sweden.
Imre PavoEli Lilly Regional Operations GmbH, Vienna, Austria.
Andrea MariInstitute of Neurosciences, National Research Council, Padova, Italy.
Mark I McCarthyOxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Hartmut RuettenSanofi-Aventis Deutschland GmbH, R&D, Frankfurt am Main, Germany.
Mark WalkerInstitute of Cellular Medicine (Diabetes), Newcastle University, Newcastle upon Tyne, UK.
Ewan PearsonPopulation Health & Genomics, Medical Research Institute, University of Dundee, Dundee, DD1 9SY, UK. e.z.pearson@dundee.ac.uk.ORCID 0000-0001-9237-8585
Paul W FranksDepartment of Clinical Sciences, Lund University Diabetes Centre, Genetic and Molecular Epidemiology Unit, CRC, Skåne University Hospital Malmö, Building 91, Level 10, Jan Waldenströms gata 35, SE-205 02, Malmö, Sweden. paul.franks@med.lu.se.ORCID 0000-0002-0520-7604
IMI DIRECT Consortium

Funding

Medical Research Council MC_UU_12015/3Wellcome TrustWellcome Trust 102820/Z/13/Z
6 · The paper itself

Abstract

aims/hypothesisHere, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and 48 months of follow-up).

methodsFrom a sampling frame of 24,682 adults of European ancestry enrolled in population-based cohorts across Europe, participants at varying risk of glycaemic deterioration were identified using a risk prediction algorithm (based on age, BMI, waist circumference, use of antihypertensive medication, smoking status and parental history of type 2 diabetes) and enrolled into a prospective cohort study (n = 2127) (cohort 1, prediabetes risk). We also recruited people from clinical registries with type 2 diabetes diagnosed 6-24 months previously (n = 789) into a second cohort study (cohort 2, diabetes). Follow-up examinations took place at ~18 months (both cohorts) and at ~48 months (cohort 1) or ~36 months (cohort 2) after baseline examinations. The cohorts were studied in parallel using matched protocols across seven clinical centres in northern Europe.

resultsUsing ADA 2011 glycaemic categories, 33% (n = 693) of cohort 1 (prediabetes risk) had normal glucose regulation and 67% (n = 1419) had impaired glucose regulation. Seventy-six per cent of participants in cohort 1 was male. Cohort 1 participants had the following characteristics (mean ± SD) at baseline: age 62 (6.2) years; BMI 27.9 (4.0) kg/m CONCLUSIONS/

interpretationThe IMI DIRECT cohorts are intensely characterised, with a wide-variety of metabolically relevant measures assessed prospectively. We anticipate that the cohorts, made available through managed access, will provide a powerful resource for biomarker discovery, multivariate aetiological analyses and reclassification of patients for the prevention and treatment of type 2 diabetes.

Indexed as

AgedBiomarkersBlood GlucoseCohort StudiesDiabetes Mellitus, Type 2FemaleGlucoseGlucose Tolerance TestHumansMaleMetforminMiddle AgedPrediabetic StateProspective StudiesBiomarkersBlood GlucoseGlucoseMetforminDietEctopic fatGenomeGlycaemic controlInsulin secretionInsulin sensitivityPersonalised medicinePhysical activityPrediabetesType 2 diabetes

Identifiers

PMID31203377
PMCPMC6677872

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.